Hohnloser J H, Schierl R, Hasford B, Emmerich B
Medizinische Klinik, Ludwig-Maximilians-Universität München, Germany.
Eur J Med Res. 1996 Sep 20;1(11):509-14.
Patients with advanced testicular cancer (TC) have a very good long-term prognosis owing to cisplatin-based polychemotherapy. Platinum is believed to be excreted at a rapid rate via urine within weeks after chemotherapy. As a new, highly sensitive method has become available detecting even natural background platinum levels in body fluids, this study was set up to analyze urinary and serum platinum levels in long-term survivors of testicular neoplasm after cisplatin based polychemotherapy and to correlate clinical data with urinary and serum platinum levels. Urinary platinum concentrations were measured in 64 healthy controls (C) and 22 male patients (TC) 150 to 3022 days after the last application of i.v. cisplatin using voltammetry after UV-photolysis. In the latter group (TC), serum platinum levels were measured as well. Clinical data were analysed as to long-term organ toxicity. Mean urinary platinum levels were 2700 times higher in the patient group (TC) than natural background noise (p < 0.0001). There was a decline of urinary and serum platinum levels over time, being significantly above normal even 8 years after cisplatin exposure. The only significant variables related to the urine platinum concentration were a) the interval between the last i.v. cisplatin application and time of study and b) the total dose given. Not significant were the number of chemotherapy cycles, pre-therapy renal disease, patient age, tumour resection before/after chemotherapy, site of pre/post therapy resection, clinical staging, histological subtypes or tumour markers. Post-therapy renal disease or peripheral nerve damage were not significantly associated with urinary platinum levels. Our data indicate that even 8 years after cisplatin based chemotherapy 500 times elevated urinary and serum platinum levels can be measured in testicular cancer patients. No organ toxicity related to long-term platinum excretion could be detected. This may be due to our small sample size.
由于基于顺铂的多药化疗,晚期睾丸癌(TC)患者具有非常良好的长期预后。据信,铂在化疗后数周内通过尿液快速排出。由于一种新的、高度灵敏的方法已可用于检测体液中甚至天然背景铂水平,本研究旨在分析基于顺铂的多药化疗后睾丸肿瘤长期存活者的尿铂和血清铂水平,并将临床数据与尿铂和血清铂水平相关联。在最后一次静脉注射顺铂后150至3022天,使用紫外光解后的伏安法测量了64名健康对照者(C)和22名男性患者(TC)的尿铂浓度。在后一组(TC)中,也测量了血清铂水平。分析了关于长期器官毒性的临床数据。患者组(TC)的平均尿铂水平比天然背景噪声高2700倍(p < 0.0001)。尿铂和血清铂水平随时间下降,即使在接触顺铂8年后仍显著高于正常水平。与尿铂浓度相关的唯一显著变量是:a)最后一次静脉注射顺铂与研究时间之间的间隔;b)给予的总剂量。化疗周期数、治疗前肾病、患者年龄、化疗前后肿瘤切除情况、治疗前后切除部位、临床分期、组织学亚型或肿瘤标志物均无显著意义。治疗后肾病或周围神经损伤与尿铂水平无显著关联。我们的数据表明,即使在基于顺铂的化疗8年后,仍可在睾丸癌患者中测量到尿铂和血清铂水平升高500倍。未检测到与长期铂排泄相关的器官毒性。这可能是由于我们的样本量较小。